Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports

摘要: Aims Cardiac resynchronization therapy (CRT) is an important treatment for heart failure that requires constant ventricular pacing, placing a high energy burden on CRT defibrillators (CRT-D). Longer battery life reduces the need device changes and associated complications, thereby affecting patient outcomes cost of care. We therefore investigated time to depletion CRT-D from different manufacturers compared these results with manufacturers' published product performance reports (PPRs). Methods All recipients at our institution between January 2008 December 2010 were included in this study cohort. The patients followed up endpoint otherwise censored death, last follow-up, or removal any reason other than depletion. A total 621 [173 Boston Scientific (BSC), 391 Medtronic (MDT), 57 St. Jude Medical (SJM)] median 3.7 (IQR 1.6–5.0) years, during which 253 (41%) devices replaced Compared MDT devices, was 85 54% less likely happen BSC SJM respectively ( P < 0.001 pairwise comparisons). Product all significantly overestimated longevity by more 20% 6 years after implantation. Conclusions Large differences exist manufacturers. Industry-published PPRs overestimate longevity. These data have implications patients, healthcare professionals, hospitals, third-party payers.